This article is more than 5 years old. Information may no longer be current.
Recent approvals in rheumatology
Click Here to Manage Email Alerts
Healio Rheumatology has compiled a list of some treatments that have been approved in rheumatology during the last several months.
Health Canada approves Kevzara for rheumatoid arthritis
Health Canada has approved Kevzara for the treatment of patients with rheumatoid arthritis who had an inadequate response or intolerance to a biologic or non-biologic disease-modifying antirheumatic drug, according to a company press release. Read More.
European Commission approves adalimumab biosimilar for treatment of RA, PsA, AS, JIA
The European Commission has approved Amgevita, a biosimilar to adalimumab, for all of its available indications. Read More.
FDA approves biosimilar for infliximab
The FDA has approved Merck and Samsung Bioepis’ infliximab biosimilar for injection, which is known as infliximab-abda (Renflexis). It will maintain the same indications as the reference product. Read More.
FDA approves Actemra for giant cell arteritis
“Rheumatologists will finally have available an option for their patients that is going to allow them to discontinue steroids as rapidly as possible,” Christine Birchwood, PhD, senior medical science director from Genentech, told Healio Rheumatology. “It is the first new therapy these patients will have had in more than 50 years.” Read More.
FDA approves Kevzara for rheumatoid arthritis
After a resubmission by Sanofi and Regeneron Pharmaceuticals Inc., the FDA has approved Kevzara for the treatment of patients with rheumatoid arthritis, according to a company press release. Read More.